LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Summary

This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.

Timeline

Start

2022-07-22

Primary completion

2024-10-15

Completion

2025-12-31

Publications

• Maher TM, Hamblin MJ, Choi WI, Case AH, Tomos IP, Tzouvelekis AE, Shore JE, Bergna MA, Golod D, Elenko E, Zhang Y, Graham CS, Song JW, Kulkarni T; ELEVATE IPF Investigators (listed in Supplementary Appendix). Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial. Am J Respir Crit Care Med. 2026 Apr 2:aamag155. doi: 10.1093/ajrccm/aamag155. Online ahead of print.

Drugs

Indications